Eli Lilly and Co. is buying a Waltham biotech in a deal valued at around $3.2 billion.
The startup being acquired is Morphic Holding Inc., a Waltham company working on treatments for chronic diseases such as types of inflammatory bowel disease.
STAY IN THE KNOW
 |
Watch NBC10 Boston news for free, 24/7, wherever you are. |
 |
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters. |
Indianapolis-based Lilly plans to acquire all outstanding shares of Morphic for $57 per share in cash. The purchase price at closing is a premium of around 79% to the closing stock price on Friday.
More on this story from Boston Business Journal
Get top local stories in Boston delivered to you every morning. Sign up for NBC Boston's News Headlines newsletter.
